Approved clinical trial of tpn171, a new class 1.1 anti pulmonary hypertension drug from Shanghai Institute of Medicine

It is learned from Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences that tpn171 and its tablets, a new drug for the treatment of pulmonary hypertension (PAH) 1.1, independently developed by Shen Jingshan research group and Jiang Hualiang research group of the Institute, have recently obtained the "drug clinical trial approval" issued by the state food and Drug Administration (CFDA), and have been approved for clinical research Pulmonary hypertension is a serious disease that endangers human life and health Its main feature is the progressive increase of pulmonary vascular resistance The lips of patients are blue purple due to hypoxia, so it is called "blue lips" If not actively treated, most patients will die of right heart failure within 2-3 years after diagnosis, so the disease is also known as "malignant tumor of cardiovascular system" At present, there are few kinds of first-line drugs for the treatment of pulmonary hypertension in China, which are expensive Drugs such as bosentan and alisentan need tens of thousands of yuan per month, and they have toxic and side effects on liver Sildenafil, as a drug for the treatment of pulmonary hypertension, is not listed in China, although it is listed abroad Patients with pulmonary hypertension in China are in the situation of no good drugs available Tpn171's scientific research team got innovative inspiration from the historical accumulation of traditional Chinese medicine and natural product chemistry of Shanghai Institute of medicine Compounds with high phosphodiesterase (PDE5) inhibitory activity were found in the extract of epimedium, and the natural product Epimedium flavone was taken as the leading structure, with the analysis data of computational chemistry as reference, through structural modification and splicing synthesis technology Finally, tpn171, a better candidate compound for comprehensive evaluation of drug-forming properties than sildenafil, was obtained Tpn171 has high activity, good selectivity and safety, low dosage and high bioavailability It is expected that patients only need to take orally once a day (dose 5-10mg), which is convenient Tpn171 active ingredients and tablets are easy to obtain with simple technology If they are successfully marketed, they are expected to become "a good drug for the common people in China" In the preclinical study, the researchers found that tpn171 has better efficacy and safety in the treatment of erectile dysfunction (ED) It is reported that tpn171 has applied for patent in 12 countries / regions and has been authorized by 8 countries / regions including Europe, the United States and Japan The new drug project was supported by major national new drug development projects, Shanghai Science and Technology Commission and other special projects It is also another new drug development achievement made by the construction of Drug Innovation Research Institute of Chinese Academy of Sciences.